series event

2022 Heath Clark Lecture with Professor Thomas Scriba

Vaccination against Mycobacterium tuberculosis (M. tb) infection and Tuberculosis (TB) disease

Event card with text: 2022 Heath Clark Lecture with Professor Thomas Scriba

Join this year's third installment of Heath Clark lecture where Professor Thomas Scriba will discuss Vaccination against Mycobacterium tuberculosis (M. tb) infection and Tuberculosis (TB) disease. 

TB is and has been a major cause of morbidity and mortality in humans for centuries. Prevention of TB, ideally through prophylactic vaccination, is a key priority of efforts to control the global TB epidemic.  

This talk will discuss vaccination against TB through the lens of the work done at the South African Tuberculosis Vaccine Initiative (SATVI) in the Western Cape of South Africa, a region heavily burdened by TB. It will outline a brief history of vaccination against TB, highlight vaccine development challenges faced and how these are being addressed, review the current state of TB vaccine development as well as efforts to discover immunological correlates of protection against TB in humans. 


Professor Thomas Scriba, University of Cape Town and SATVI 

Professor Thomas Scriba

Dr Tom Scriba (PhD) is Professor in Immunology at the Department of Pathology, University of Cape Town and Co-Director of SATVI, where directs the Clinical Immunology Laboratory. He trained in biological sciences at Stellenbosch University and obtained a DPhil (PhD) in T cell immunology at Oxford University. He returned to South Africa in 2006 to complete a postdoctoral fellowship in paediatric and clinical immunology in TB and vaccinology at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town.  

Dr Scriba’s research interests include immunopathogenesis of infectious disease, and in particular M. tb, development of immuno-diagnostics, development of novel TB vaccines, discovery of immune correlates of risk of TB disease and correlates of protection against M. tb infection and TB disease. He has been co-investigator in 30 trials of novel TB vaccine candidates conduced at SATVI and is Co-PI of the Immune Correlates Consortium, which aims to discover immune correlates of protection in samples collected in recent phase 2b trials of BCG and M72:ASO1E.  

Other Heath Clark Lectures in 2022

Please note that you can join this event in person or you can watch a live broadcast. The live broadcast link will be announced on this page in due course. 


Free and open to all. No registration required.